HomeCompareCHYMF vs MRK

CHYMF vs MRK: Dividend Comparison 2026

CHYMF yields 2.34% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $34.6K in total portfolio value
10 years
CHYMF
CHYMF
● Live price
2.34%
Share price
$0.30
Annual div
$0.01
5Y div CAGR
-0.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.1K
Annual income
$260.58
Full CHYMF calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — CHYMF vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCHYMFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CHYMF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CHYMF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CHYMF
Annual income on $10K today (after 15% tax)
$198.76/yr
After 10yr DRIP, annual income (after tax)
$221.49/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, MRK beats the other by $8,375.22/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CHYMF + MRK for your $10,000?

CHYMF: 50%MRK: 50%
100% MRK50/50100% CHYMF
Portfolio after 10yr
$40.4K
Annual income
$5,187.18/yr
Blended yield
12.84%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

CHYMF
No analyst data
Altman Z
2.0
Piotroski
4/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CHYMF buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCHYMFMRK
Forward yield2.34%2.81%
Annual dividend / share$0.01$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-0.4%32.7%
Portfolio after 10y$23.1K$57.7K
Annual income after 10y$260.58$10,113.78
Total dividends collected$2.5K$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CHYMF vs MRK ($10,000, DRIP)

YearCHYMF PortfolioCHYMF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,933$232.90$11,213$373.04$280.00MRK
2$11,935$237.02$12,667$512.06$732.00MRK
3$13,012$240.86$14,439$708.14$1.4KMRK
4$14,167$244.42$16,640$988.16$2.5KMRK
5$15,406$247.71$19,432$1,394.07$4.0KMRK
6$16,735$250.76$23,057$1,992.90$6.3KMRK
7$18,160$253.55$27,889$2,894.79$9.7KMRK
8$19,688$256.11$34,518$4,286.29$14.8KMRK
9$21,324$258.45$43,912$6,494.35$22.6KMRK
10$23,078$260.58$57,714$10,113.78$34.6KMRK

CHYMF vs MRK: Complete Analysis 2026

CHYMFStock

Cahya Mata Sarawak Berhad, an investment holding company, engages in the manufacturing and trading of cement and construction materials, construction, road maintenance, township, and property and infrastructure development businesses in Malaysia. It operates through seven segments: Cement, Construction Materials and Trading, Road Maintenance, Construction, Property Development, Phosphate, and Samalaju Development. The company offers Portland cement; clinker and ready-mix concrete products; pre-cast concrete products, including pre-stressed beams for bridges and other uses, reinforced concrete square piles, box culverts, kerbs, and cement sand bricks; and industrialized building systems, such as wall panels, pre-cast columns and beams, half slabs, hollow blocks, and staircases. It also provides microtonalite, granite, and limestone; delivery, grading, and pavement laying services; steel drawn wires and wire mesh; residential, commercial, and township development, management, and consultancy services; management of temporary accommodation services; supervisory, general trading, software and IT support, education, technical, machinery, and motor vehicle rental services; rehabilitation and maintenance for roads; and construction and road maintenance equipment, as well as supplies premix and road maintenance contractor works. In addition, the company undertakes general construction and infrastructure projects; distributes road and general construction materials, water treatment materials, electrical pipes equipment, and mechanical spare parts; rents investment properties; owns and operates hotels and lodges; and manufactures food, feed, and fertilizer phosphate products. Further, it engages in the mixed-use development and project management activities; and construction of telecommunication towers, as well as undertakes civil engineering, building, and utilities works. The company was founded in 1974 and is headquartered in Kuching, Malaysia.

Full CHYMF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this CHYMF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CHYMF vs SCHDCHYMF vs JEPICHYMF vs OCHYMF vs KOCHYMF vs MAINCHYMF vs JNJCHYMF vs ABBVCHYMF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.